Skip to content
LexBuild

Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin

---
identifier: "/us/fr/2012-22195"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin"
title_number: 0
title_name: "Federal Register"
section_number: "2012-22195"
section_name: "Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin"
positive_law: false
currency: "2012-09-10"
last_updated: "2012-09-10"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2012-22195"
document_type: "notice"
publication_date: "2012-09-10"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "77 FR 55481"
fr_volume: 77
docket_ids:
  - "Docket No. FDA-2012-N-0902"
effective_date: "2012-09-20"
fr_action: "Notice."
---

#  Withdrawal of Approval of New Animal Drug Applications; Chorionic Gonadotropin; Naloxone; Oxymorphone; Oxytocin

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The Food and Drug Administration (FDA) is withdrawing approval of four new animal drug applications (NADAs) at the sponsor's request because the products are no longer manufactured or marketed.

**DATES:**

Withdrawal of approval is effective September 20, 2012.

**FOR FURTHER INFORMATION CONTACT:**

David Alterman, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-453-6843, email: *[email protected].*

**SUPPLEMENTARY INFORMATION:**

The sponsors in table 1 of this document have requested that FDA withdraw approval of the four NADAs listed  because the products are no longer manufactured or marketed.

| NADA No. | Trade name (drug) | Applicant |
| --- | --- | --- |
| 030-525 | NUMORPHAN (oxymorphone hydrochloride) Injection | Endo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317. |
| 035-825 | NARCAN (naloxone hydrochloride) Injection | Endo Pharmaceuticals Inc., 100 Painters Dr., Chadds Ford, PA 19317. |
| 046-822 | VETOCIN (oxytocin) Injection | United Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711. |
| 103-090 | CHORTROPIN (chorionic gonadotropin) Injection | United Vaccines, A Harlan Sprague Dawley, Inc., Co., P.O. Box 4220, Madison, WI 53711. |

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 *Notice of withdrawal of approval of application* (21 CFR 514.116), notice is given that approval of NADAs 030-525, 035-825, 046-822, and 103-090, and all supplements and amendments thereto, is hereby withdrawn, effective September 20, 2012.

Elsewhere in this issue of the *Federal Register* , FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Dated: September 5, 2012.

Bernadette Dunham,

Director, Center for Veterinary Medicine.